DMT-treated patients | First Treatment Course | |||||||
---|---|---|---|---|---|---|---|---|
Oral | Injectable | Infusion | ||||||
Duration of follow-up (mean, SD), mo | 62.3 | 30.1 | 51.7 | 25.1 | 63.6 | 30.5 | 61.5 | 29.6 |
First DMT treatment course | ||||||||
Patients with first DMT course (n, %) | 14,627 | 100 | 1583 | 100 | 12,796 | 100 | 248 | 100 |
Time to first DMT (mean, SD), mo | 5.7 | 12.7 | 16.2 | 22.7 | 4.1 | 9.5 | 18.1 | 24.4 |
Time on first DMT (mean, SD), mo | 28.1 | 25.9 | 21.0 | 17.5 | 29.0 | 26.7 | 27.2 | 25.4 |
First DMT end (n, %) | ||||||||
Switch | 2450 | 16.7 | 140 | 8.8 | 2287 | 17.9 | 23 | 9.3 |
Discontinuation (≥60-day gap) | 7447 | 50.9 | 741 | 46.8 | 6613 | 51.7 | 93 | 37.5 |
End of follow-up period | 4730 | 32.3 | 702 | 44.3 | 3896 | 30.4 | 132 | 53.2 |
Second DMT treatment course | ||||||||
Patients with second DMT (n, %) | 7510 | 51.3 | 541 | 34.2 | 6898 | 53.9 | 71 | 28.6 |
Treatment gap (mean, SD), mo | 5.1 | 9.3 | 4.6 | 6.4 | 5.2 | 9.6 | 5.9 | 7.7 |
Time on second DMT (mean, SD), mo | 15.1 | 17.4 | 11.7 | 11.7 | 15.3 | 17.7 | 13.7 | 15.3 |
Second DMT end (n, %) | ||||||||
Switcha | 899 | 12.0 | 42 | 7.8 | 845 | 12.2 | 12 | 16.9 |
Discontinuation (≥60-day gap)a | 4172 | 55.6 | 277 | 51.2 | 3856 | 55.9 | 39 | 54.9 |
End of follow-up perioda | 2439 | 32.5 | 222 | 41.0 | 2197 | 31.8 | 20 | 28.2 |
Third DMT treatment course | ||||||||
Patients with third DMT (n, %) | 3882 | 26.5 | 200 | 12.6 | 3645 | 28.5 | 37 | 14.9 |
Treatment gap (mean, SD), mo | 5.0 | 7.2 | 4.7 | 6.0 | 5.0 | 7.3 | 3.8 | 5.4 |
Time on third DMT (mean, SD), mo | 11.7 | 13.9 | 8.8 | 9.3 | 11.9 | 14.1 | 13.8 | 15.2 |
Third DMT end (n, %) | ||||||||
Switchb | 428 | 11.0 | 15 | 7.5 | 404 | 11.1 | 9 | 24.3 |
Discontinuation (≥60-day gap)b | 2248 | 57.9 | 100 | 50.0 | 2131 | 58.5 | 17 | 45.9 |
End of follow-up periodb | 1206 | 31.1 | 85 | 42.5 | 1110 | 30.5 | 11 | 29.7 |